FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *   Valamehr Bahram 2. Date of Event Requiring Statement (Month/Day/Year) 07/31/2018 3. Issuer Name and Ticker or Trading Symbol FATE THERAPEUTICS INC [FATE] (Last) (First) (Middle) C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Development Officer 5. If Amendment, Date Original Filed(Month/Day/Year) (Street) SAN DIEGO, CA 92121 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock (1) 27,958 D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	  (2)	07/17/2028	Common Stock	150,000	$ 11.03	D	Â
Stock Option (right to buy)	  (3)	01/15/2028	Common Stock	214,800	$ 6.55	D	Â
Stock Option (right to buy)	  (4)	01/03/2027	Common Stock	120,000	$ 2.73	D	Â
Stock Option (right to buy)	  (5)	01/07/2026	Common Stock	88,080	$ 2.9	D	Â
Stock Option (right to buy)	  (6)	01/05/2025	Common Stock	10,704	$ 4.84	D	Â
Stock Option (right to buy)	  (7)	01/09/2024	Common Stock	8,500	$ 6.62	D	Â
Stock Option (right to buy)	  (7)	08/11/2023	Common Stock	1,536	$ 7.87	D	Â
Stock Option (right to buy)	  (7)	01/13/2023	Common Stock	423	$ 1.37	D	Â
Stock Option (right to buy)	  (7)	03/11/2021	Common Stock	3,076	$ 1.69	D	Â
Stock Option (right to buy)	  (7)	02/10/2020	Common Stock	1,153	$ 1.69	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Valamehr Bahram C/O FATE THERAPEUTICS, INC. 3535 GENERAL ATOMICS COURT, SUITE 200 SAN DIEGO, CA 92121	Â	Â	  Chief Development Officer	Â

Signatures

/s/ Cindy R. Tahl, as Attorney-in-Fact		08/07/2018
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Award of Restricted Stock Units, where 10,458 of the underlying shares are vested and 17,500 of the underlying shares vest on October 12, 2019. This grant is subject to an accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
(2)	The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 18, 2018 such that this option is fully exercisable on July 18, 2022.
(3)	The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 16, 2018 such that this option is fully exercisable on January 16, 2022.
(4)	The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 4, 2017 such that this option is fully exercisable on January 4, 2021.
(5)	The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 8, 2016 such that this option is fully exercisable on January 8, 2020.
(6)	The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on February 5, 2015 such that this option is fully exercisable on January 5, 2019.
(7)	This option is fully vested.
  Remarks: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.